Merial Introduces New Molecular Technology to PUREVAX® Recombinant FeLV Vaccine to Provide Improved Potency
Only non-adjuvanted feline leukemia vaccine to be available in convenient subcutaneous injectable
Duluth, Ga. Today at the North American Veterinary Conference (NAVC) in Orlando, Fla., Merial announced PUREVAX® Recombinant FeLV - the newest addition to the only non-adjuvanted line of feline vaccines in the U.S. Delivered subcutaneously, PUREVAX features improved potency, and has a lower antigen concentration than the previous PUREVAX Recombinant Leukemia Vaccine.1 It will be available in early spring 2012.